CAMBRIDGE, Mass., Sept. 26, 2024 ~ Apnimed, Inc., a pharmaceutical company specializing in the development of oral therapies for sleep-related breathing diseases, has announced its participation in the 4th Annual Needham Private Biotech Company Virtual 1x1 Forum on October 8-9, 2024.

The company will be hosting virtual investor meetings on Tuesday, October 8th. This event will provide an opportunity for Apnimed to showcase its latest product, AD109, which has the potential to be the first pharmacological treatment to improve oxygenation during sleep by directly addressing the underlying neuromuscular cause of upper airway collapse in people with obstructive sleep apnea (OSA).

AD109 is a combination of aroxybutynin, a novel antimuscarinic, and atomoxetine, a selective noradrenaline reuptake inhibitor (NRI). This unique combination targets the root cause of OSA and is designed to be taken once nightly as an oral pill. By simplifying intervention and addressing the underlying neuromuscular dysfunction present in all OSA cases, AD109 may help more people benefit from effective and restorative sleep.

More on Boston Chron

• Get to know Dr. Raphael E. Cuomo, PhD, Professor and Scientist at the University of California, San Diego
• Ohio Medicare (Plan Brian C. Moore), has once again been distinguished as Ohio's Top-Ranked and Number-One-Rated "Best Choice" Medicare Expert!
• Honoring Dr. King: A Commitment to Justice and Equity in Boston
• Boston: A Step Toward Safer Streets for All
• Vital Village Networks Selects Leaders for 2025 Community Food Systems Fellowship

Obstructive sleep apnea is a serious chronic sleep-related breathing disease that affects over 54 million people in the U.S. and 1 billion people worldwide. It is characterized by repeated collapses of the upper airway during sleep, leading to intermittent oxygen deprivation. This can have serious long-term health consequences such as high blood pressure, cardiovascular disease, and type 2 diabetes.

Despite its prevalence and potential health risks, OSA remains underdiagnosed and undertreated. Many individuals with OSA either refuse or underutilize treatment options due to their complexity or invasiveness. Currently available treatments also do not address the underlying neuromuscular dysfunction present in all cases of OSA.

Apnimed aims to change this by providing novel oral therapies that simplify intervention and improve oxygenation for people living with OSA and other sleep-related breathing diseases. The company is also working on a joint venture with Shionogi & Co., Ltd, called Shionogi Apnimed Sleep Science (SASS), to expand its reach to other sleep-related breathing diseases.

Based in Cambridge, Massachusetts, Apnimed is dedicated to revolutionizing the treatment landscape for sleep-related breathing diseases. Through their innovative approach, they hope to elevate the health and expectations of everyone in the sleep-related breathing disease community.

For more information about Apnimed and their products, visit their website at apnimed.com or follow them on social media platforms such as X and LinkedIn.

Media Contact:

Brian Ritchie

Investor Contact:

---

Show All News | Report Violation